DAAM2 serves as a pivotal downstream effector for SIRT1 to exert immune-regulatory effects in the bone microenvironment; thus, targeting DAAM2 can treat osteoporosis by increasing CD4<sup>+</sup> CTL responses. This evidence concerns the gene SIRT1 and osteoporosis.